[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ID23503A - Garam-garam sertralina dan bentuk-bentuk sediaan lepas-lambat dari sertralina - Google Patents

Garam-garam sertralina dan bentuk-bentuk sediaan lepas-lambat dari sertralina

Info

Publication number
ID23503A
ID23503A IDW991704A ID991704A ID23503A ID 23503 A ID23503 A ID 23503A ID W991704 A IDW991704 A ID W991704A ID 991704 A ID991704 A ID 991704A ID 23503 A ID23503 A ID 23503A
Authority
ID
Indonesia
Prior art keywords
sertralina
sales
detailed forms
mga
sertraline
Prior art date
Application number
IDW991704A
Other languages
English (en)
Inventor
Mary Tanya Am Ende
William John Curatolo
Hylar Lewis Friedman
Ravi Mysore Shanker
Scott Max Herbig
Dwayne Thomas Friesen
James Blair West
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ID23503A publication Critical patent/ID23503A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IDW991704A 1997-07-01 1998-06-15 Garam-garam sertralina dan bentuk-bentuk sediaan lepas-lambat dari sertralina ID23503A (id)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5142097P 1997-07-01 1997-07-01
US5141497P 1997-07-01 1997-07-01
US5149897P 1997-07-01 1997-07-01
US5140297P 1997-07-01 1997-07-01

Publications (1)

Publication Number Publication Date
ID23503A true ID23503A (id) 2000-04-27

Family

ID=27489408

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW991704A ID23503A (id) 1997-07-01 1998-06-15 Garam-garam sertralina dan bentuk-bentuk sediaan lepas-lambat dari sertralina

Country Status (33)

Country Link
US (1) US6517866B1 (id)
EP (1) EP0999830A1 (id)
JP (1) JP2000514101A (id)
KR (2) KR100412327B1 (id)
CN (1) CN1256085C (id)
AP (1) AP1526A (id)
AR (2) AR015919A1 (id)
AU (1) AU739261B2 (id)
BG (1) BG103915A (id)
BR (1) BR9810403A (id)
CA (1) CA2290966C (id)
CO (1) CO4940402A1 (id)
DZ (1) DZ2546A1 (id)
EA (1) EA002482B1 (id)
HK (1) HK1026630A1 (id)
HR (1) HRP980379B1 (id)
HU (1) HUP0002296A3 (id)
ID (1) ID23503A (id)
IL (2) IL152330A0 (id)
IS (1) IS5265A (id)
MY (1) MY129175A (id)
NO (1) NO996518L (id)
NZ (2) NZ513456A (id)
OA (1) OA11245A (id)
PA (1) PA8454401A1 (id)
PE (1) PE88699A1 (id)
PL (1) PL337806A1 (id)
SK (1) SK180499A3 (id)
TN (1) TNSN98125A1 (id)
TR (1) TR199903280T2 (id)
TW (1) TWI241188B (id)
UY (1) UY25067A1 (id)
WO (1) WO1999001121A1 (id)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040208926A1 (en) * 1997-07-01 2004-10-21 Pfizer Inc Solubilized sertraline compositions
WO1999051208A1 (en) * 1998-04-03 1999-10-14 Bm Research A/S Controlled release composition
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
IE990406A1 (en) 1999-05-20 2000-12-27 Elan Corp Plc Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
HU229569B1 (hu) * 1999-05-20 2014-02-28 Elan Pharma Int Ltd Szelektív szerotoninújrafelvétel-gátlók szabályozott kibocsátású többrészecskés kiszerelései
CA2383785C (en) 1999-09-03 2009-02-17 Eli Lilly And Company Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
GB9923045D0 (en) * 1999-09-29 1999-12-01 Novartis Ag New oral formulations
MXPA02006335A (es) 1999-12-23 2002-12-13 Pfizer Prod Inc Forma de dosificacion de farmaco en capas impulsada por hidrogel.
US6620431B1 (en) * 2000-04-17 2003-09-16 Charles Signorino Shellac film coatings providing release at selected pH and method
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
WO2002017918A2 (en) 2000-08-30 2002-03-07 Pfizer Products Inc. Sustained release formulations for growth hormone secretagogues
US6482440B2 (en) * 2000-09-21 2002-11-19 Phase 2 Discovery, Inc. Long acting antidepressant microparticles
SE0004671D0 (sv) 2000-12-15 2000-12-15 Amarin Dev Ab Pharmaceutical formulation
JP2002212062A (ja) * 2001-01-24 2002-07-31 Teijin Ltd 遅延放出制御組成物
JPWO2002064114A1 (ja) * 2001-02-15 2004-06-10 株式会社三和化学研究所 新規眼科用組成物
EP1385486A4 (en) * 2001-04-18 2006-05-17 Nostrum Pharmaceuticals Inc NEW COATING OF SLOW RELEASE PHARMACEUTICAL COMPOSITION
JP2004536855A (ja) * 2001-07-16 2004-12-09 アストラゼネカ・アクチエボラーグ プロトンポンプ阻害剤および酸中和剤を含む医薬製剤
WO2003024429A1 (en) * 2001-09-21 2003-03-27 Egalet A/S Polymer release system
US20040253310A1 (en) * 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
MXPA04002976A (es) * 2001-09-28 2005-06-20 Johnson & Johnson Formas de dosificacion con un nucleo interior y una cobertura externa.
US7005138B2 (en) * 2001-12-21 2006-02-28 Duramed Pharmaceuticals, Inc. Method of systematically delivering SSRIs
US7670612B2 (en) 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
US20100189797A1 (en) 2002-06-10 2010-07-29 Julien Mendlewicz Oral antidepressant formulation
US20050226926A1 (en) * 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
JP2006504693A (ja) * 2002-09-16 2006-02-09 セプラコア インコーポレーテッド トランス４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロ−ｎ−メチル−１−ナフタレンアミンによるｃｎｓ障害の治療
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
CA2415154C (en) * 2002-12-24 2009-06-16 Biovail Laboratories Inc. Modified release formulations of selective serotonin re-uptake inhibitors
WO2004065348A1 (en) * 2003-01-23 2004-08-05 Pfizer Products Inc. Pharmaceutically acceptable salts of sertraline and pharmaceutical compositions thereof
PL378108A1 (pl) * 2003-02-14 2006-03-06 Combinatorx, Incorporated Leczenie łączone do terapii zapalnych zaburzeń immunologicznych
EP1610767B1 (en) 2003-03-26 2011-01-19 Egalet A/S Morphine controlled release system
JP2006522099A (ja) * 2003-04-04 2006-09-28 ファルマシア コーポレーション 複合粒状体からなる経口徐放性圧縮錠
ES2368066T3 (es) 2003-04-24 2011-11-14 Jagotec Ag Comprimido de liberación retardada con geometría de nucleo definida.
EP1626950A4 (en) * 2003-05-23 2007-05-23 Transform Pharmaceuticals Inc SERTRALINZUSAMMENSETZUNGEN
JP2007521231A (ja) * 2003-08-08 2007-08-02 バイオヴェイル ラボラトリーズ インコーポレイテッド 塩酸ブプロピオンの放出調節錠剤
US7893300B2 (en) * 2003-11-04 2011-02-22 Cipla Limited Process for the preparation of polymorphs of selective serotonin reuptake inhibitor
AR048033A1 (es) * 2004-03-12 2006-03-22 Smithkline Beecham Plc Composicion farmaceutica para moldear componentes que comprende copolimero de poli(met)acrilato, cubierta, conector o espaciador de capsula moldeado por inyeccion que tiene la composicion farmaceutica y forma de dosificacion farmaceutica de multicomponentes a partir de dicha composicion
KR100772980B1 (ko) * 2004-04-01 2007-11-02 한미약품 주식회사 메트포르민의 경구투여용 서방성 제제
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
ITMI20041295A1 (it) * 2004-06-25 2004-09-25 Cosmo Spa Composizioni farmaceutiche antimicrobiche orali
EP2286801A3 (en) 2004-08-13 2012-05-09 Boehringer Ingelheim International GmbH Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
KR100920856B1 (ko) * 2004-11-30 2009-10-09 (주)아모레퍼시픽 선택적 세로토닌 재흡수 억제제의 연장방출 제제 및 그제조방법
WO2006072878A1 (en) * 2005-01-07 2006-07-13 Ranbaxy Laboratories Limited Oral dosage forms of sertraline having controlled particle size and processes for their preparation
US20080274183A1 (en) * 2005-02-04 2008-11-06 Phillip Michael Cook Thermoplastic articles containing a medicament
JP5020931B2 (ja) * 2005-03-14 2012-09-05 サン・ファーマ・アドバンスド・リサーチ・カンパニー・リミテッド 経口薬剤送達システム
CN101188999B (zh) * 2005-06-03 2012-07-18 尹格莱特股份有限公司 用于递送分散在分散介质中的活性物质的药物传递系统
US8747897B2 (en) 2006-04-27 2014-06-10 Supernus Pharmaceuticals, Inc. Osmotic drug delivery system
US7893053B2 (en) * 2006-06-16 2011-02-22 Theracos, Inc. Treating psychological conditions using muscarinic receptor M1 antagonists
AU2007280636B2 (en) 2006-08-03 2013-07-18 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid disease
CA2930487A1 (en) * 2007-01-16 2008-07-24 Egalet Ltd. Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i)mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
WO2008148798A2 (en) 2007-06-04 2008-12-11 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
WO2009034431A2 (en) 2007-09-10 2009-03-19 Pfizer Inc. Controlled-release dosage forms for varenicline
AU2009281537A1 (en) * 2008-08-14 2011-06-30 Bioneer A/S Coated tablets with a remaining degradation surface over the time
DE102008051572A1 (de) 2008-09-05 2010-03-11 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Herstellung von Phosphatbindern und auf diese Weise hergestellte Phosphatbinder
AU2008243202B2 (en) * 2008-11-11 2015-08-20 Cosmo Technologies Ltd Oral antimicrobial pharmaceutical compositions
WO2010089132A1 (en) 2009-02-06 2010-08-12 Egalet A/S Immediate release composition resistant to abuse by intake of alcohol
CA2766179A1 (en) 2009-06-24 2010-12-29 Egalet Ltd. Controlled release formulations
JP2013509963A (ja) 2009-11-09 2013-03-21 スポットライト テクノロジー パートナーズ エルエルシー 断片化ヒドロゲル
WO2011057131A1 (en) 2009-11-09 2011-05-12 Spotlight Technology Partners Llc Polysaccharide based hydrogels
CA2877183A1 (en) 2012-07-06 2014-01-09 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
JP6041823B2 (ja) 2013-03-16 2016-12-14 ファイザー・インク トファシチニブの経口持続放出剤形
WO2016020936A2 (en) * 2014-07-21 2016-02-11 Patel Jayendrakumar Dasharathlal A novel oral gastroretentive pharmaceutical dosage form
CN104402705B (zh) * 2014-11-04 2017-04-12 成都理工大学 球形柠檬酸钙及其制备方法和应用
JP6455293B2 (ja) * 2015-04-21 2019-01-23 ニプロ株式会社 セルトラリン及び／又はその薬学上許容しうる塩を含む製剤
CA3078143A1 (en) * 2017-10-05 2019-04-11 Purac Biochem B.V. Lactate powder and method for the preparation thereof
CN109432038A (zh) * 2018-12-28 2019-03-08 乐普制药科技有限公司 一种含有盐酸舍曲林的肠溶片剂及其制备方法
CN118522388B (zh) * 2024-07-25 2024-10-11 北京科技大学 二元复配有机缓蚀剂优化方法、装置、设备及介质

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4536518A (en) * 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
DK150008C (da) 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US4847092A (en) 1985-11-12 1989-07-11 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulations
US5112619A (en) 1985-11-12 1992-05-12 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulation
US4797286A (en) 1985-11-12 1989-01-10 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulations
US4803076A (en) 1986-09-04 1989-02-07 Pfizer Inc. Controlled release device for an active substance
DE3700420A1 (de) 1986-12-22 1988-07-07 Efka Werke Kiehn Gmbh Fritz Tabakerzeugnis fuer die selbstverfertigung einer zigarette, insbesondere filter-zigarette
US5135947A (en) 1987-04-09 1992-08-04 Eli Lilly And Company 1-phenyl-3-naphthalenyloxypropanamines and their use as selective serotonin reuptake inhibitors
US4792448A (en) 1987-06-11 1988-12-20 Pfizer Inc. Generic zero order controlled drug delivery system
US4839104A (en) 1987-06-11 1989-06-13 Pfizer, Inc. Process for preparing sertraline intermediates
US4777288A (en) 1987-06-11 1988-10-11 Pfizer Inc. Process for preparing a 4,4-diphenylbutanoic acid derivative
US4971998A (en) 1987-10-22 1990-11-20 Massachusetts Institute Of Technology Methods for treating the premenstrual or late luteal phase syndrome
US4876282A (en) 1987-11-25 1989-10-24 Eli Lilly And Company 1-Phenylalkylamines as selective serotonin uptake inhibitors
US4855500A (en) 1988-05-04 1989-08-08 Pfizer Inc. Process for preparing a ketimine
US5026707A (en) 1988-05-23 1991-06-25 Eli Lilly And Company Ring-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes
IL91398A (en) * 1988-08-30 1994-05-30 Pfizer A device for the controlled release of pneumatic substances, including the active substance, surrounded by an asymmetric membrane
IL114715A (en) 1989-02-27 1997-01-10 Lilly Co Eli Intermediate compounds for ring-substituted 2-amino-1, 2, 3, 4-tetrahydronaphthalenes and 3-aminochromanes
US4981870A (en) 1989-03-07 1991-01-01 Pfizer Inc. Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants
US4983401A (en) 1989-05-22 1991-01-08 Kinaform Technology, Inc. Sustained release pharmaceutical preparations having pH controlled membrane coatings
DK0415612T3 (da) 1989-08-30 1993-12-13 Pfizer Anvendelse af sertralin til behandling af afhængigheder af kemiske stoffer
US4940731A (en) 1989-08-30 1990-07-10 Pfizer Inc. Method of treating premature ejaculation using sertraline
US5130338A (en) 1989-08-30 1992-07-14 Pfizer Inc. Method of treating chemical dependencies using sertraline
US4962128A (en) * 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
AU8072691A (en) 1990-06-28 1992-01-23 Beecham Group Plc Pharmaceutical preparations
ATE118345T1 (de) 1990-08-07 1995-03-15 Pfizer Verwendung von interfacial polymerisierten membranen in abgabevorrichtungen.
WO1992002215A1 (en) 1990-08-09 1992-02-20 Massachusetts Institute Of Technology Method for treating the premenstrual or late luteal phase syndrome
US5104899A (en) 1990-08-13 1992-04-14 Sepracor, Inc. Methods and compositions for treating depression using optically pure fluoxetine
AU658155B2 (en) 1990-11-24 1995-04-06 Beecham Group Plc Use of paroxetine for the treatment of senile dementia, or anorexia
PT712837E (pt) 1991-02-08 2001-03-30 Lilly Co Eli 2-amino-1,2,3,4-tetra-hidronaftalenos de 3-aminocromanos de anel substituido
WO1992018005A1 (en) 1991-04-16 1992-10-29 National Institutes Of Health Method of treating trichotillomania and onychophagia
US5196607A (en) 1992-02-14 1993-03-23 Pfizer Inc. Process for preparing ketone enantiomer
EP0632720B1 (en) 1992-03-25 1998-11-11 Depomed Systems, Inc. Hydroxyethylcellulose-based sustained-release oral drug dosage froms
US5518730A (en) 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
US5248699A (en) 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
US6440457B1 (en) 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
IE930485A1 (en) 1993-06-28 1994-12-28 Hemisphere Ltd Antidepressant agents with a rapid onset of action
US5597826A (en) 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
WO1996009047A1 (en) 1994-09-19 1996-03-28 The Du Pont Merck Pharmaceutical Company Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
EP0768083B1 (en) 1995-07-17 2003-03-26 Pfizer Inc. Sertraline for treating post myocardial infarction patients
GB9514842D0 (en) 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation
WO1997035586A1 (en) 1996-03-25 1997-10-02 Eli Lilly And Company Method for treating pain
ZA97976B (en) * 1996-04-05 1997-08-18 Alza Corp Uniform drug delivery theraphy.
US5741807A (en) 1996-09-27 1998-04-21 Cytos Pharmaceuticals, L.P. Histidine compositions and methods for treating or preventing infectious and non-infectious diarrheas
US6590083B1 (en) 1999-04-16 2003-07-08 Ortho-Mcneil Pharmaceutical, Inc. Ketolide antibacterials

Also Published As

Publication number Publication date
EP0999830A1 (en) 2000-05-17
HRP980379B1 (en) 2003-04-30
AR065827A2 (es) 2009-07-08
WO1999001121A1 (en) 1999-01-14
TWI241188B (en) 2005-10-11
SK180499A3 (en) 2001-08-06
BG103915A (en) 2000-07-31
CN1261793A (zh) 2000-08-02
AR015919A1 (es) 2001-05-30
KR20010014043A (ko) 2001-02-26
HUP0002296A3 (en) 2001-11-28
IL133080A0 (en) 2001-03-19
EA002482B1 (ru) 2002-06-27
OA11245A (en) 2003-07-23
MY129175A (en) 2007-03-30
HUP0002296A2 (hu) 2001-10-28
KR100412327B1 (ko) 2003-12-31
PA8454401A1 (es) 2000-05-24
KR20040004367A (ko) 2004-01-13
PE88699A1 (es) 1999-09-20
TR199903280T2 (xx) 2000-11-21
TNSN98125A1 (fr) 2005-03-15
AP1526A (en) 2006-01-03
DZ2546A1 (fr) 2003-02-08
NZ513456A (en) 2003-02-28
AU739261B2 (en) 2001-10-11
US6517866B1 (en) 2003-02-11
IL152330A0 (en) 2003-05-29
AU7544998A (en) 1999-01-25
UY25067A1 (es) 2000-12-29
CO4940402A1 (es) 2000-07-24
NO996518L (no) 2000-02-29
CN1256085C (zh) 2006-05-17
JP2000514101A (ja) 2000-10-24
KR100446366B1 (ko) 2004-09-01
NO996518D0 (no) 1999-12-28
NZ501251A (en) 2001-09-28
CA2290966A1 (en) 1999-01-14
EA199900964A1 (ru) 2000-08-28
IS5265A (is) 1999-11-23
AP9801281A0 (en) 1998-06-30
PL337806A1 (en) 2000-09-11
BR9810403A (pt) 2000-08-29
HRP980379A2 (en) 1999-04-30
HK1026630A1 (en) 2000-12-22
CA2290966C (en) 2005-12-20

Similar Documents

Publication Publication Date Title
ID23503A (id) Garam-garam sertralina dan bentuk-bentuk sediaan lepas-lambat dari sertralina
WO1997025955A3 (en) Sanitary napkin with perfume-bearing microcapsule adhesive
BG102200A (en) Transcorneal system for the release of a medicament
GT199800126A (es) Terapia de combinacion.
MX9204268A (es) Una composicion para la liberacion prolongada y controlada de substancias medicamentosas y un proceso para preparar la misma.
AR038434A2 (es) Compuesto 14,15-dihidro-16-oxoparahercuamida y compuestos 2-desoxo de parahercuamida y marcfortina
YU53899A (sh) Primena inhibitora ciklooksigenaze-2 u prevenciji kardiovaskularnih poremećaja
SE9803680L (sv) Strålningshärdbara, cyanoakrylatinnehållande ko mpositioner
ES2099419T3 (es) Nabumetona pulverizada en frio.
BR9806213A (pt) Forma de dosagem transdérmica.
BR9815747A (pt) Composição para liberação de aroma
BG102696A (en) Antipsoriasic nail varnish
ITCO970020A0 (it) Valvola di sicurezza e di morosita'
DE69619341D1 (de) Sicherheitsblatt, dessen Dicke beinahe konstant ist
NO996519L (no) Doseringsformer av sertralin med forsinket frigjøring
HUP0302738A2 (hu) SARP-1 alkalmazása scleroderma kezelésére és megelőzésére
FR2761641B1 (fr) Dispositif d'actionnement pour l'actionnement, notamment l'actionnement pneumatique d'un embrayage a friction
EA200000112A1 (ru) Новая композиция
ATE323493T1 (de) Gesteuerte freisetzung von antidepressiva
BR9802363A (pt) Dispositivo para comando de um estado de embreamento de uma embreagem
FR2732219B1 (fr) Compositions pharmaceutiques pour la prevention et le traitement du paludisme, a base d'un membre de la famille des chondroitine-glycosaminoglycanes
KR910011390U (ko) 브레이크 배력장치의 키 부재의 빠짐방지장치
ATE204286T1 (de) Modifizierte alpha-d-glcp-(1,2)-alpha-d-glcp-(1, 3)-alpha-d-glcp-analoge
KR950023564A (ko) 배력장치의 시일부재 빠짐방지장치
IT1284374B1 (it) Graffa di fissagio e sua utilizzazione.